Annexon, Inc. (NASDAQ:ANNX) Shares Sold by Kennedy Capital Management LLC

Kennedy Capital Management LLC cut its stake in Annexon, Inc. (NASDAQ:ANNX - Free Report) by 24.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,091,834 shares of the company's stock after selling 359,061 shares during the quarter. Kennedy Capital Management LLC owned about 1.02% of Annexon worth $5,601,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of ANNX. The Manufacturers Life Insurance Company increased its position in shares of Annexon by 1.6% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 159,586 shares of the company's stock worth $945,000 after purchasing an additional 2,450 shares during the last quarter. E Fund Management Co. Ltd. lifted its position in shares of Annexon by 36.0% during the 4th quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company's stock worth $79,000 after purchasing an additional 4,086 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Annexon by 1.8% during the 4th quarter. Wellington Management Group LLP now owns 268,166 shares of the company's stock worth $1,376,000 after acquiring an additional 4,806 shares in the last quarter. Rhumbline Advisers boosted its holdings in Annexon by 4.3% in the fourth quarter. Rhumbline Advisers now owns 141,852 shares of the company's stock valued at $728,000 after purchasing an additional 5,854 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of Annexon by 2.8% in the 4th quarter. Bank of New York Mellon Corp now owns 230,546 shares of the company's stock valued at $1,183,000 after buying an additional 6,226 shares during the last quarter.

Remove Ads

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $16.00 price target on shares of Annexon in a research report on Tuesday, March 4th. HC Wainwright restated a "buy" rating and set a $30.00 target price on shares of Annexon in a research report on Tuesday, December 17th.

Annexon Stock Up 0.7 %

Shares of Annexon stock traded up $0.01 during trading on Tuesday, hitting $1.54. 1,963,119 shares of the company were exchanged, compared to its average volume of 1,805,264. The firm has a 50 day moving average price of $2.43 and a 200 day moving average price of $4.52. The stock has a market capitalization of $168.95 million, a price-to-earnings ratio of -1.47 and a beta of 1.24. Annexon, Inc. has a fifty-two week low of $1.29 and a fifty-two week high of $7.85.

Annexon (NASDAQ:ANNX - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.05). Analysts predict that Annexon, Inc. will post -0.96 earnings per share for the current year.

Annexon Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.